IgE, allergic diseases, and omalizumab

Current Pharmaceutical Design

Volumn 12, Issue 30, 2006, Pages 3929-3944

  DuBuske, L M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Immunology Research Institute of New England   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allergy; Asthma; IgE; Omalizumab; Rhinitis

Indexed keywords

ADRENALIN; ALLERGEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; CELL SURFACE RECEPTOR; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; CYTOKINE; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; PLACEBO;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BASOPHIL; BREAST CANCER; CELL SURFACE; CLINICAL TRIAL; COLLAPSE; COMORBIDITY; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FOOD ALLERGY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; INCIDENCE; INFLAMMATORY DISEASE; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MELANOMA; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PAROTID GLAND CANCER; PATHOPHYSIOLOGY; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REVIEW; SINUSITIS; SKIN CANCER; SKIN DISEASE; SKIN TEST; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E;

EID: 33749853618     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559641     Document Type: Review

References (100)

1. Ramirez MA. Horse asthma following blood transfusion: report of a case. JAMA 1919; J3: 984-5.
2. Prausnitz C, Küstner H. Studien über Uberempfindlicht. Centralb Baketerial 1 Abt Orig 1921; 86: 160-9, Originally published, in English, in Prausnitz C. In: Gell PGH, Coombs RRA Eds, Clinical aspects of immunology. Oxford, Blackwell. 1962; 808-16.
3. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97: 75-85.
4. Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967; 99: 1187-98.
5. Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13: 381-94.
6. Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967; 2: 951-3.
7. Bennich HH, Ishizaka K, Johansson SG, Rowe DS, Stanworth DR, Terry WD. Immunoglobulin E, a new class of human immunoglobulin. Immunology 1968; 15: 323-4.
8. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine Production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996; 183: 1303-10.
9. Gould H, Sutton B, Beavil A, Edmeades R, Martin D. Immunoglobulin E Receptors. Clin Exp Allergy 1991; 21(Suppl 1): 138-47.
10. Sutton BJ, Gould HJ. The human IgE network. Nature 1993; 366: 421-8.
11. Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337: 187-9.
12. Wang B, Rieger A, Kilgus O, Ochiai K, Maurer D, Fodinger D, et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J Exp Med 1992; 175: 1353-65.
13. Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, et al. Peripheral blood dendritic cells express Fe epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 1996; 157: 607-16.
14. Maurer D, Fiebiger E, Reininger B, Wolff-Winiski B, Jouvin MH, Kilgus O, et al. Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals. J Exp Med 1994; 179: 745-50.
15. Gounni AS, Lamkhioued B, Delaporte E, Dubost A, Kinet JP, Capron A, et al. The high-affinity IgE receptor on eosinophils: from allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 1994; 94: 1214-6.
16. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367: 183-6.
17. Joseph M, Gounni AS, Kusnierz JP, Vorng H, Sarfati M, Kinet JP, et al. Expression and functions of the high-affinity IgE receptor on human platelets and megakaryocyte precursors. Eur J Immunol 1997; 27: 2212-8.
18. Campbell AM, Vachier I, Chanez P, Vignola AM, Lebel B, Kochan J, et al. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics. Am J Respir Cell Mol Biol 1998; 19: 92-7.
19. MacGlashan D, McKenzie-White J, Chichester K, Bochner BS, Davis FM, Schroeder JT, et al. In vitro regulation of FcεRI expression on human basophils by IgE antibody. Blood 1998; 91: 1633-43.
20. Rajakulasingam K, Durham SR, O'Brien F, Humbert M, Barata LT, Reece L, et al. Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J Allergy Clin Immunol 1997; 100: 78-86.
21. Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 2003; 112: 1132-8.
22. Delespesse G, Sarfati M, Wu CY, Fournier S, Letellier M. The low-affinity receptor for IgE. Immunol Rev 1992; 125: 77-97.
23. Nye L, Merrett TG, Landon J, White RJ. A detailed investigation of circulating IgE levels in a normal population. Clin Allergy 1975; 5: 13-24.
24. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271-7.
25. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325: 1067-71.
26. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323: 502-7.
27. Sporik R, Ingram JM, Price W, Sussman JH, Honsinger RW, Platts-Mills TA. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon's breath. Am J Respir Crit Care Med 1995; 151: 1388-92.
28. Squillace SP, Sporik RB, Rakes G, Couture N, Lawrence A, Merriam S, et al. Sensitization to dust mites as a dominant risk factor for asthma among adolescents living in Central Virginia. Multiple regression analysis of a population-based study. Am J Respir Crit Care Med 1997; 156: 1760-4.
29. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518.
30. Cockcroft DW, Murdock KY. Changes in bronchial responsiveness to histamine at intervals after allergen challenge. Thorax 1987; 42: 302-8.
31. National Center for Health Statistics, Centers for Disease Control and Prevention. Asthma prevalence, health care use, and mortality, 2002 [Online]. 2006 April 7 [cited 2006 July 5]. Available from: URL: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm
32. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ 2002; 51: 1-13.
33. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92: 32-9.
34. National Heart, Lung and Blood Institute. Morbidity & mortality: 2004 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health; May 2004.
35. Cisternas, MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111: 1212-8.
36. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996; 9: 636-42.
37. Ford ES, Mannino DM, Homa DM, Gwynn C, Redd SC, Moriarty DG, et al. Self-reported asthma and health-related quality of life: findings from the behavioral risk factor surveillance system. Chest 2003; 123: 119-27.
38. Vollmer WM, Markson LE, O'Conner E, Sanocki LL, Fitterman L, Berger M, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160: 1647-52.
39. Osman LM, Calder C, Robertson R, Friend JA, Legge JS, Douglas JG. Symptoms, quality of life, and health service contact among young adults with mild asthma. Am J Respir Crit Care Med 2000; 161: 498-503.
40. National Heart, Lung and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health; 2004. Publication 02-3659.
41. National Heart, Lung and Blood Institute. National asthma education and prevention program. Expert panel report 2: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 97-4051.
42. National Heart, Lung and Blood Institute. National asthma education and prevention program. Expert panel report: Guidelines for the diagnosis and management of asthma - update on selected topics 2002. Bethesda, MD: National Institutes of Health; 2003. Publication 02-5074.
43. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-7.
44. Apter AJ, Boston RC, George M, Norfleet AL, Tenhave T, Coyne JC, et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: It's not just black and white. J Allergy Clin Immunol 2003; 111: 1219-26.
45. Rona RJ. Asthma and poverty. Thorax 2000; 55: 239-44.
46. Aberg N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989; 19: 59-63.
47. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108(5 Suppl): S147-334.
48. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104: 301-4.
49. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998; 28(Suppl 2): 3-10.
50. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway hyperresponsiveness. J Allergy Clin Immunol 1993; 91: 97-101.
51. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62: 125-34.
52. Kennedy E. Sinusitis [Online]. 2005 Nov 28 [cited 2006 July 5]. Available from: URL: http://www.emedicine.com/EMERG/topic536.htm
53. Cook K, Walsh M. Otitis media [Online]. 2005 May 23 [cited 2006 July 5]. Available from: URL: http://www.emedicine.com/EMERG/topic351.htm
54. Stool SE, Field MJ. The impact of otitis media. Pediatr Infect Dis J 1989; 8: S11-14.
55. Bernstein JM, Lee J, Conboy K, Ellis E, Li P. Further observations on the role of IgE-mediated hypersensitivity in recurrent otitis media with effusion. Otolaryngol Head Neck Surg 1985; 93: 611-5.
56. Skoner DP, Stillwagon PK, Casselbrandt M, Tanner EP, Doyle WJ, Fireman P. Inflammatory mediators in chronic otitis media with effusion. Arch Otolaryngol Head Neck Surg 1988; 114: 1131-3.
57. Sicherer SH. Food Allergy. Lancet 2002; 360: 701-10.
58. Sampson HA, Sicherer SH, Birnbaum AH. AGA technical review on the evaluation of food allergy in gastrointestinal disorders. Gastroenterology 2001; 120: 1026-40.
59. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999; 104: S114-S122.
60. Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW Jr, Hamilton RG. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Biotechnology (NY) 1990; 8: 122-6.
61. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-32.
62. Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman C, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: 26368-73.
63. Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308-12.
64. Xolair (omalizumab). Pulmonary-allergy drugs advisory committee meeting [Online]. 2003 May 15 [cited 2006 July 05]. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3952B1_01Genentech-Xolair.htm
65. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon) expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-45.
66. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-40.
67. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-34.
68. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004; 113: e308-12.
69. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36.
70. Xolair [package insert]. East Hanover (NJ):Genentech Inc. and Novartis Pharmaceutical Corp; 2003.
71. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-21.
72. Adelroth E, Rak S, Hahhtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-9.
73. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491-8.
74. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90.
75. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.
76. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154-9.
77. Buhl, R, Solèr M, Matz J, Townley R, O'Brien J, Noga O. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Resp J 2002; 20: 73-8.
78. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182-8.
79. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111: 278-84.
80. Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088-94.
81. Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002; 110: e55.
82. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
83. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8.
84. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16.
85. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-17.
86. Holgate ST, Chuchalin AG, Herbert J, Lotvall J, Persson GB, Chung KF, et al, for the Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-8.
87. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701-8.
88. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma. Chest 2004; 125: 1378-86.
89. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-40.
90. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2956-67.
91. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
92. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003; 24: 323-9.
93. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Am Allergy Asthma Immunol 2003; 91: 160-7.
94. Food and Drug Administration. BLA STN 103976/0 Review of clinical safety data [Online]. 2003 June 20 [cited 2006 July 05]. Available from: URL: http://www.fda.gov/cder/biologics/review/omalgen062003r1.pdf
95. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-80.
96. Ownby DR. A history of latex allergy. J Allergy Clin Immunol 2002; 110: S27-32.
97. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113: 360-1.
98. Luskova, P. and Draber, P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des. 2004; 10(15):1727-37.
99. Mitsumori, S. Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases. Curr Pharm Des. 2004; 10(28): 3533-8.
100. Wu, Z.; MacPhee, I. A., and Oliveira, D. B. Reactive oxygen species in the initiation of IL-4 driven autoimmunity as a potential therapeutic target. Curr Pharm Des. 2004; 10(8): 899-913.